Clinical Trials Browser

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT04991103 2025-12-31

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

Phase 2 Recruiting

40 enrolled

Plasma cell

Amyloidosis, Multiple Myeloma, Neoplasm, Residual

NCT07285044 2025-12-22

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

Phase 2 Recruiting

27 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidMyeloidPlasma cellThoracic

Amyloidosis, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Basal Cell, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Hodgkin Disease, Lung Neoplasms, Melanoma, Multiple Myeloma, Myelodysplastic Syndromes, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Lymphoma, Mantle-Cell

Clinical Trials

Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

MICA

Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis

Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis

Daratumumab for Patients With Light Chain Amyloidosis

A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis

Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis

Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease

124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis

DUAL

Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL)

CATALYST

Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis

Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis

Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis

PET

Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF

ViGeM

Safety and Effect of Doxycycline in Patients With Amyloidosis

Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment

LENDEXAL

A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis

Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis

Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis

Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis